JP Morgan Says ResMed Bundling Issue Is Less Of A Problem

JP Morgan analyst Steve Wheen said that

bundling issue is shaping up to be less of a problem than he previously thought. Based on this, the firm has returned to its original investment thesis in which it recognized such things as ResMed's product offering and R&D initiatives. Shares of ResMed are up about 1.6 percent following the JP Morgan comments.